Foliglurax

From WikiMD.org
Jump to navigation Jump to search

Foliglurax

Foliglurax (pronounced: /foʊˈlɪgjʊræks/) is a novel pharmacological agent currently under investigation for its potential therapeutic applications in the treatment of Parkinson's disease.

Etymology

The term "Foliglurax" is derived from the Latin words 'folium' meaning leaf and 'glura' meaning glue, symbolizing the drug's potential to 'stick' to the targeted receptors in the brain and 'leaf' through the symptoms of Parkinson's disease.

Pharmacology

Foliglurax is a selective metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator. It works by enhancing the activity of the mGluR4 receptor, which is believed to have a neuroprotective effect in the dopaminergic system. This mechanism of action is thought to potentially alleviate the motor symptoms associated with Parkinson's disease.

Clinical Trials

Foliglurax has undergone Phase II clinical trials for the treatment of Parkinson's disease. The results have shown promise in reducing the motor complications and non-motor symptoms in patients with advanced Parkinson's disease.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski